DSP107, a Novel CD47x4-1BB targeting agent
Time: 1:30 pm
day: Day One Track B PM
Details:
Virtual Presentation
- Improving Target Specificity and Activity Through the Use of Bispecific Fusion Protein
- Designing bispecific agent to successfully mediate dual activation of innate and adaptive immune systems
- Transforming safety profile and avoiding hematological toxicities
- Enhancing the potential for the treatment of solid and hematological malignancies
